May 20, 2024

OWP Pharmaceuticals Announces FDA Filing Acceptance for New Drug Application of SUBVENITE® (lamotrigine) Oral Suspension

Share this press release:

Document loads below this notification. If you are not able to see the document below, please reload page.

Additional Press Releases

August 1, 2023 / Press Release

OWP Pharmaceuticals Announces IND Authorization for First Oral Liquid Formulation of Trazodone for Treatment of MDD

March 14, 2023 / Press Release

Powering Social Enterprise with Profit and Purpose: The Tandem Hybrid by Scott Boyer, Jeremy Gudauskas, and Mike Hamel

November 30, 2022 / Press Release

OWP Pharmaceuticals Announces Patent Application for First Oral Liquid Formulation of Trazodone for Treatment of MDD